[Use of pseudomonas immunoglobulin in ventilated patients at an interdisciplinary surgical intensive care station].
The clinical efficacy and safety of a new pseudomonas hyperimmune globulin for intravenous administration were examined in 30 patients in a prospective randomized study. Although the statistical evaluation of the measurable parameters did not show relevant differences between the therapy group (n = 15) and the controls (n = 15), the clinical course of the disease was markedly better in patients treated with hyperimmune globulin. In the control group, three patients died from Pseudomonas aeruginosa infections, but none in the therapy group. The preparation was very well tolerated.
D002986:Clinical Trials as Topic; D003428:Cross Infection / Q000628:therapy*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D007362:Intensive Care Units; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000276:immunology*; D011897:Random Allocation; D012121:Respiration, Artificial
D007074:Immunoglobulin G
Einsatz von Pseudomonas-Immunglobulin bei beatmeten Patienten einer interdisziplinären chirurgischen Intensivstation.